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Abstract
When RBL-2H3 rat basophilic leukemia cells were stimulated by antigen or the Ca2 ionophore A23187, the activity to
increase histamine production by rat bone marrow cells in the conditioned medium increased time-dependently. To
characterize the histamine-production-increasing factor (HPIF) produced by RBL-2H3 cells, the conditioned medium was
collected 8 h after stimulation by A23187, and the factor was purified by three-step chromatography, the specific activity
being increased by 9000-fold. The partial amino acid sequence of the peptide obtained by S. aureus V8 protease digestion was
identical to the internal amino acid sequence of rat granulocyte-macrophage colony-stimulating factor (GM-CSF). In
addition, GM-CSF mRNA levels in RBL-2H3 cells were increased by A23187 with a peak at 4 h. Furthermore, recombinant
rat GM-CSF increased histamine production by rat bone marrow cells. These findings suggested that HPIF produced by the
stimulated RBL-2H3 cells is GM-CSF. Possible significant roles of HPIF at the late phase of allergic inflammation are
discussed. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Histamine plays crucial roles in immune and in-
£ammatory reactions via H1 and H2 receptors. In
an air pouch-type allergic in£ammation in rats, the
histamine content in the pouch £uid increases bi-
phasically [1]. At the anaphylaxis phase, histamine
is released from mast cells in subcutaneous tissues
and elicits a transient increase in vascular perme-
ability via H1 receptors [2]. In contrast, the contin-
uous increase in histamine levels in the pouch £uid
at the late phase is not due to mast cell degranula-
tion, but to the increase in de novo synthesis of
histamine [3]. Histamine at the late phase does not
contribute to the increase in vascular permeability
but plays a role in down-regulation of leukocyte
in¢ltration into the in£ammatory site via H2 recep-
tors [1].
We suggested that the increase in HDC activity at
the late phase is regulated by proteinaceous factor(s)
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which has the activity to increase the production of
histamine by bone marrow cells [3]. The histamine-
production-increasing activity in the pouch £uid in-
creased from 4 to 24 h after antigen challenge and
was followed by an increase in HDC activity in the
pouch wall tissue [3]. We partially puri¢ed a factor
having histamine-production-increasing activity from
the pouch £uid and named it histamine-production-
increasing factor (HPIF) [4]. It is a sugar protein
whose molecular mass and pI value are about 30
kDa and 4^5, respectively, indicating that biochemi-
cally HPIF resembles GM-CSF [5].
In the present study, we found that the condi-
tioned medium of RBL-2H3 cells stimulated by anti-
gen or the Ca2 ionophore A23187 has an activity to
increase histamine production by bone marrow cells.
Therefore, we attempted to characterize the factor
responsible for this activity in the conditioned me-
dium of RBL-2H3 cells.
2. Materials and methods
2.1. Stimulation of RBL-2H3 cells and preparation of
conditioned medium
RBL-2H3 cells obtained from the Japanese Cancer
Research Resources Bank were maintained in 5%
CO2 at 37‡C in Eagle’s minimum essential medium
(EMEM) (Nissui Seiyaku, Tokyo, Japan) containing
10% (v/v) fetal bovine serum (Flow Laboratories,
Mclean, VA, USA). The cells were harvested by tryp-
sin (0.25%, w/v) and EDTA (0.02%, w/v) in phos-
phate-bu¡ered saline (PBS), suspended at 5.0U105
cells/ml in EMEM and were incubated at 37‡C in
an atmosphere of 5% CO2-95% air in a 175 cm2
plastic tissue culture £ask (Nunc, Roskilde, Den-
mark). When a con£uent monolayer had developed,
the cells were washed twice with prewarmed EMEM,
and stimulated with EMEM containing DNP-HSA
(50 ng/ml, Sigma, St. Louis, MO, USA) or A23187
(0.1 WM, Calbiochem, La Jolla, CA, USA) for speci-
¢ed time periods. The conditioned medium was then
collected and centrifuged at 220Ug for 3 min at
4‡C. The supernatant fraction was dialyzed against
250-fold volumes of 20 mM Tris-HCl bu¡er
(pH 8.0). The bu¡er was exchanged every 12 h for
7 days.
2.2. Measurement of histamine-production-increasing
activity
Histamine-production-increasing activity in the
conditioned medium was assayed according to the
method described by Filho et al. [6] with slight mod-
i¢cations. Namely, bone marrow cells were collected
from tibiae and femurs of male rats of the Sprague-
Dawley strain (speci¢c pathogen-free, Charles River
Japan, Kanagawa, Japan) and adjusted to 1.0U107
cells/ml in EMEM. Four hundred microliters of the
cell suspension, 50 Wl of each sample and 350 Wl of
EMEM were added into each well of 12-well plastic
tissue culture plates (Coster, Cambridge, MA, USA)
and incubated for 24 h at 37‡C in an atmosphere of
5% CO2-95% air. The conditioned medium was col-
lected and centrifuged at 220Ug for 3 min. Hista-
mine contents in the supernatant fraction were meas-
ured £uorometrically as described by Shore et al. [7].
When the e¡ect of recombinant rat GM-CSF
(PharMingen, San Diego, CA, USA) on histamine
production was examined, 400 Wl of EMEM contain-
ing various concentrations of recombinant rat GM-
CSF were added to 400 Wl of the cell suspension
(1.0U107 cells/ml) in each well of the 12-well plates,
incubated at 37‡C for various periods, and hista-
mine contents in the supernatant fraction of the
conditioned medium were determined as described
above.
2.3. Puri¢cation of histamine-production-increasing
factor
The supernatant fraction of the conditioned me-
dium (3 l) collected 8 h after stimulation with
A23187 (0.1 WM) was concentrated to 300 ml using
an ultra¢ltration membrane (YM10, molecular
weight cut o¡: 10 kDa, Amicon, Lexington, MA,
USA) and dialyzed against 20 mM Tris-HCl bu¡er
(pH 8.0) as described above. The concentrated con-
ditioned medium was applied onto a Resource Q 1 ml
column (0.64U3 cm) (Pharmacia Biotech., Uppsala,
Sweden) equilibrated with 20 mM Tris-HCl bu¡er
(pH 8.0) and eluted with a linear gradient of increas-
ing concentration of NaCl at a £ow rate of 1 ml/min/
fraction. The fractions containing histamine-produc-
tion-increasing activity were pooled, dialyzed against
distilled water, concentrated by lyophilization, and
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loaded onto a Superose 12 PC 3.2/30 column
(3.2U30 cm) (Pharmacia Biotech.) equilibrated with
PBS containing 0.01% (v/v) Tween 80. The protein
was eluted with the same bu¡er at a £ow rate of
0.3 ml/min/fraction. The active fractions were
pooled, loaded onto a Resource RPC 3 ml column
(6.4U100 mm) (Pharmacia Biotech.) and eluted with
a three-stage linear gradient of increasing concentra-
tions of solvent B (0.1% tri£uoroacetic acid in ace-
tonitrile) starting with a 5 min gradient to 30% sol-
vent B, continuing with a 25 min gradient to 50%
solvent B, and ¢nishing with a 5 min gradient to
100% solvent B at a £ow rate of 1 ml/min/fraction.
The active fractions were then pooled, lyophilized,
reconstituted in PBS, loaded onto a WRPC C2/C18
SC 2.1/10 column (2.1U100 mm) (Pharmacia Bio-
tech.), and eluted with a two-stage linear gradient
of increasing concentration of solvent B starting
with a 25 min gradient to 50% solvent B and ¢nish-
ing with a 5 min gradient to 100% solvent B at a £ow
rate of 150 Wl/min. The histamine-production-in-
creasing activity in each fraction was determined as
described above.
2.4. SDS-PAGE analysis of the puri¢ed protein
Discontinuous sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) was per-
formed as described by Laemmli [8]. Twelve and a
half percent polyacrylamide gel (Wako Pure Chem-
icals, Osaka, Japan) containing 0.375 M Tris-HCl
bu¡er (pH 8.8) and 0.1% sodium dodecyl sulfate
(SDS, Wako Pure Chemicals), and 4% polyacryl-
amide gel containing 0.125 M Tris-HCl bu¡er (pH
6.8) and 0.1% SDS were used as the separating gel
and the stacking gel, respectively. The electrophoresis
bu¡er was 25 mM Tris containing 0.192 M glycine
and 0.1% SDS (pH 8.3). Before electrophoresis, sam-
ples were reduced with 10% 2-mercaptoethanol in 50
mM Tris-HCl bu¡er (pH 6.8) containing SDS and
20% glycerol. SDS-PAGE was performed at constant
current of 20 mA for 4 h. After electrophoresis, pro-
teins were visualized by silver staining using Silver
Stain II Kit Wako (Wako Pure Chemicals). Molec-
ular weight marker ‘Daiichi’WIII (Daiichi Pure Chem-
icals, Tokyo, Japan) containing phosphorylase b
(97.4 kDa), albumin (66.0 kDa), aldolase (42.4
kDa), carbonic anhydrase (30.0 kDa), trypsin inhib-
itor (20.0 kDa) and lysozyme (14.4 kDa) was used as
molecular weight standard.
2.5. Restric digestion of the puri¢ed protein by
S. aureus V8 protease
The protein eluted from WRPC C2/C18 SC 2.1/10
column (Pharmacia Biotech.) was lyophilized and re-
constituted in 100 Wl of 20 mM ammonium bicarbon-
ate bu¡er (pH 7.8). S. aureus V8 protease (10 Wg,
Wako Pure Chemicals) was then added and incu-
bated at 37‡C for 16 h. The peptides obtained by
the restric digestion were separated with WRPC C2/
C18 SC 2.1/10 column (Pharmacia Biotech.).
2.6. Analysis of amino acid sequence
Amino acid sequence analysis was performed using
an Applied Biosystems Model 477A pulse-liquid-
phase sequencer (Applied Biosystems, Foster City,
CA, USA). The phenylthiohydantoin derivatives of
amino acids were analyzed by an Applied Biosystems
120A on-line system.
2.7. Determination of GM-CSF mRNA levels by the
reverse transcription-polymerase chain reaction
(RT-PCR) method
RBL-2H3 cells were stimulated with A23187 (0.1
WM) at 37‡C for 0, 1, 2, 4 and 8 h. Total RNA in the
RBL-2H3 cells was prepared by acid guanidinium
thiocyanate-phenol-chloroform extraction [9], and
the yield of RNA isolated was determined by spec-
trophotometry. One microgram of RNA from each
sample was reverse transcribed at 37‡C for 1 h in
40 Wl of the bu¡er (50 mM Tris-HCl, 75 mM KCl,
3 mM MgCl2, pH 8.3) containing 5 WM of random
hexamer oligonucleotides (Gibco BRL, Gaithers-
burg, MD, USA), 200 U of the reverse transcriptase
from Moloney murine leukemia virus (Gibco BRL),
0.5 WM deoxynucleotide 5P-triphosphate and 10 mM
dithiothreitol. PCR primers for rat GM-CSF were
designed from the GenBank database. The sequences
of primers used were: (former) 5P-GGATCCG-
CACCCACCCGCTCACCC-3P and (reverse) 5P-
GTCGACTCATTTCTGGACCGGCTT-3P, which
amplify a 395 GM-CSF base pair (bp) fragment.
PCR was performed for 30 cycles in 50 Wl of the
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PCR bu¡er (10 mM Tris-HCl, 50 mM KCl, 1.5 mM
MgCl2, pH 8.3) containing 5 Wl of the reverse tran-
scribed RNA solution, 0.25 WM each primer, 125 WM
dNTP and 0.5 U Taq polymerase (Takara Shuzo,
Ohtsu, Shiga, Japan) using a thermal cycler Gene-
Amp PCR System 2400 (Perkin Elmer Cetus, Nor-
walk, CT, USA). Each cycle consisted of 1 min de-
naturation at 94‡C, 1 min annealing at 57‡C, and
2 min extension at 72‡C.
The rat glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) gene (housekeeping gene) was used
as an internal standard gene. PCR primers for rat
GAPDH were described by Robbins and McKinney
[10]; primers used were (former) 5P-TGATGACAT-
CAAGAAGGTGGTGAAG-3P and (reverse) 5P-
TCCTTGGAGGCCATGTAGGCCAT-3P, which
amplify a 249 bp GAPDH fragment. PCR was per-
formed for 27 cycles: 0.5 min denaturation at 94‡C,
1 min annealing at 57‡C, and 2 min extension at
72‡C. The other conditions were the same as that
for rat GM-CSF. After the PCR performance, 9 Wl
of the PCR reaction mixture was loaded onto 1.5%
(w/v) agarose gel, and the PCR products were visual-
ized by ethidium bromide staining after electropho-
resis.
Fig. 1. Time course of histamine-production-increasing activity
in the conditioned medium of DNP-HSA- and A23187-stimu-
lated RBL-2H3 cells. RBL-2H3 cells were incubated in the pres-
ence or absence of DNP-HSA (50 ng/ml) or A23187 (0.1 WM)
for the indicated periods and the conditioned medium was col-
lected. Histamine-production-increasing activity in the condi-
tioned medium was determined as described in Section 2, and
expressed as the quantity of histamine produced by bone mar-
row cells during 24 h culture. The basal quantity of histamine
produced by unstimulated bone marrow cells (100.0 þ 1.9 ng/
well) was subtracted from each value. The data are the mean-
s þ SEM from four wells. In some points, SEM were too small
to depict, i.e., they are within the symbols. Statistical signi¢-
cance: *P6 0.001 vs. corresponding control.
Fig. 2. Puri¢cation of HPIF in the conditioned medium. (A)
Anion-exchange chromatography of the conditioned medium.
The conditioned medium of A23187-stimulated RBL-2H3 cells
was collected and concentrated using a YM10 ultra¢ltration
membrane. After dialysis against 20 mM Tris-HCl bu¡er (pH
8.0), the retentate was loaded onto a Resource Q 1 ml column
and eluted with a linear gradient of increasing concentration of
NaCl. (B) Gel ¢ltration chromatography of the active fractions
eluted from Resource Q 1 ml. The active fractions eluted from
Resource Q 1 ml were pooled, dialyzed against PBS, then
loaded onto a Superose 12 PC 3.2/30 column. Molecular weight
markers used in this study were as follows: blue dextran: 2000
kDa, bovine serum albumin: 67 kDa, ovalbumin: 43 kDa, chy-
motrypsinogen: 25 kDa, ribonuclease A: 13.7 kDa. (C) Re-
verse-phase HPLC of the active fractions eluted from Superose
12 PC 3.2/30. The active fractions eluted from Superose 12 PC
3.2/30 were loaded onto a Resource RPC 3 ml column and pro-
teins were eluted with a linear gradient of increasing concentra-
tion of 0.1% (v/v) TFA-acetonitrile. Histamine-production-in-
creasing activity in each fraction is expressed as the quantity of
histamine produced by bone marrow cells during 24 h culture.
The mean basal quantity of histamine produced by the unstim-
ulated bone marrow cells is 109.0 ng/well (A), 99.0 ng/well (B)
and 104.5 ng/well (C). The basal value was subtracted from
each corresponding value.
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2.8. Statistical analysis
The results were analyzed for statistical signi¢-
cance by Student’s t-test for unpaired observations.
3. Results
3.1. Histamine-production-increasing activity in the
conditioned medium of the antigen- and
A23187-stimulated RBL-2H3 cells
When RBL-2H3 cells sensitized with DNP-speci¢c
IgE were incubated in medium containing the anti-
gen DNP-HSA (50 ng/ml) or the calcium ionophore
A23187 (0.1 WM) for indicated periods of time, his-
tamine-production-increasing activity in the condi-
tioned medium increased time-dependently and at-
tained a plateau 4 and 8 h after incubation,
respectively (Fig. 1). Since the activity in the condi-
tioned medium of the A23187-stimulated cells was
much higher than that of the DNP-HSA-stimulated
cells, we tried to purify HPIF in the conditioned
medium of the former.
3.2. Puri¢cation of HPIF
Serum-free conditioned medium (3 l) containing
900 mg protein was used as a starting material. We
employed three steps to purify HPIF from the con-
ditioned medium. In the ¢rst step, the concentrated
fraction was loaded onto a Resource Q 1 ml column.
An elution pro¢le of histamine-production-increasing
activity is shown in Fig. 2A. By increasing NaCl
concentration, histamine-production-increasing ac-
tivity was eluted. The active fractions obtained by
anion-exchange chromatography were concentrated
and loaded onto a Superose 12 PC 3.2/30 column.
The histamine-production-increasing activity was de-
tected as a single peak corresponding to 30 kDa mo-
lecular mass (Fig. 2B). The speci¢c activity was in-
creased from 74.9 to 2080 units/mg protein by the gel
¢ltration procedure. In the third step, using Resource
RPC 3 ml, histamine-production-increasing activity
was eluted in the fraction at 40.0^42.0% acetonitrile
(Fig. 2C) and the speci¢c activity was increased from
2080 to 600 000 units/mg protein. The fraction con-
taining the activity gave a sharp peak when examined
on WRPC C2/C18 SC 2.1/10 column (Fig. 3A). SDS-
PAGE analysis of the peak fraction gave a single
protein band at 30 kDa (Fig. 3B).
A summary of the puri¢cation scheme is shown in
Table 1. About 9000-fold puri¢cation was achieved
from the serum-free conditioned medium. The over-
all yield was 10% and 10 Wg of HPIF was obtained
from 3 l of the conditioned medium.
Fig. 3. Determination of purity of HPIF by reverse-phase
HPLC and SDS-PAGE. (A) Reverse-phase HPLC of the active
fractions eluted from Resource RPC 3 ml. The active fractions
eluted from Resource RPC 3 ml were pooled, lyophilized, re-
constituted in PBS, and loaded onto a WRPC C2/C18 SC 2.1/10
column. Proteins were eluted with a linear gradient of increas-
ing concentration of 0.1% (v/v) TFA-acetonitrile. (B) SDS-
PAGE analysis of the peak fraction eluted from WRPC C2/C18
SC 2.1/10. Peak fraction eluted from WRPC C2/C18 SC 2.1/10
was lyophilized, reconstituted in PBS, and analyzed by SDS-
PAGE. Proteins were visualized by silver staining.
Table 1
Puri¢cation of histamine-production-increasing factor
Stage Protein
(mg)
Activity units
(103 U)
Speci¢c activity
(U/mg)
Puri¢cation
(-fold)
Yield
(%)
Cond. medium 3 l 900 60 66.7 1 100
(1) Resource Q 1 ml 427 32 74.9 1.1 53.3
(2) Superose 12 PC 2/30 7.2 15 2 080 31.2 25.0
(3) Resource RPC 3 ml 0.01 6 600 000 9 000 10.0
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3.3. Determination of the internal amino acid
sequence of HPIF
Puri¢ed HPIF was digested by S. aureus V8 pro-
tease and the fragment peptides were separated by
reverse-phase HPLC using WRPC C2/C18 SC 2.1/10
(Fig. 4A). The amino acid sequence of peptide A is
identical to 50^63 residues of standard rat GM-CSF
(Fig. 4B). Peptide B could not be sequenced.
3.4. Determination of GM-CSF mRNA levels by
RT-PCR
The levels of GM-CSF mRNA in RBL-2H3 cells
stimulated with A23187 (0.1 WM) for the indicated
periods of time were determined. The PCR was per-
formed using speci¢c primers for rat GM-CSF and
the PCR product identi¢ed by sequence comparison
with rat GM-CSF gene. When RBL-2H3 cells were
incubated at 37‡C in medium containing A23187 (0.1
WM), the level of GM-CSF mRNA was increased
time-dependently, reaching a maximum at 4 h and
then declined at 8 h (Fig. 5). In contrast, the level of
GAPDH mRNA was constant during the incubation
period.
3.5. Histamine-production-increasing activity of
recombinant rat GM-CSF
Incubation of rat bone marrow cells in EMEM
containing various concentrations of recombinant
rat GM-CSF increased histamine production time-
dependently (Fig. 6). At 24 h, histamine production
was increased signi¢cantly by recombinant rat GM-
Fig. 4. Restric digestion of the puri¢ed HPIF by S. aureus V8
protease and determination of the partial amino acid sequence.
(A) The puri¢ed protein eluted from WRPC C2/C18 SC 2.1/10
was digested with S. aureus V8 protease and loaded onto a
WRPC C2/C18 SC 2.1/10. Peptides were then eluted with a line-
ar gradient of increasing concentration of 0.1% (v/v) TFA-ace-
tonitrile. (B) Amino acid sequence of the digested peptide was
determined using an Applied Biosystems Model 477A pulse-
liquid-phase sequencer and compared with the corresponding
amino acid sequence of standard rat GM-CSF.
Fig. 5. Time changes of mRNA levels of GM-CSF and
GAPDH in RBL-2H3 cells. RBL-2H3 cells were stimulated
with A23187 (0.1 WM) for the indicated periods of time. Total
RNA was extracted and RT-PCR was performed as described
in Section 2.
Fig. 6. E¡ects of recombinant rat GM-CSF on histamine pro-
duction by bone marrow cells. Rat bone marrow cells (4.0U106
cells) were incubated for the indicated periods of time at 37‡C
in 0.8 ml of EMEM containing the indicated concentrations of
recombinant rat GM-CSF. The data are the means þ SEM from
four wells. In some points, SEM were too small to depict, i.e.,
they are within the symbols. Statistical signi¢cance: *P6 0.001
vs. corresponding control.
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CSF at 0.3, 1.0 and 3.0 nM but not at 0.1 nM.
However, after 36 h, a signi¢cant increase in hista-
mine production was observed at all concentrations
of recombinant rat GM-CSF in a concentration-de-
pendent manner (Fig. 6). These ¢ndings indicated
that rat GM-CSF stimulates histamine production
by rat bone marrow cells.
4. Discussion
Histamine production at the late phase of allergic
in£ammation is reported to be regulated by hista-
mine releasing factor (HRF), that induces histamine
release from basophils and mast cells [11]. In con-
trast, we demonstrated that in an air pouch-type al-
lergic in£ammation model in rats, histamine produc-
tion at the late phase is regulated by HPIF [3]. HPIF
increases histamine production at the in£ammatory
site [3], whereas HRF induces release of pre-formed
histamine from mature basophils and mast cells [11].
Other than HRF, several proteins which include C-C
chemokines, such as MCAF [12,13], RANTES [14],
MIP-1K and MIP-1L [15], or p21 and p23 [16], have
histamine releasing activity. It is known that GM-
CSF and IL-3 have an activity to increase histamine
production by immature hematopoietic progenitor
cells [17,18]. However, it remains to be elucidated
whether these cytokines play a role in histamine pro-
duction at the late phase of allergic in£ammation.
Biochemical features of HPIF in the exudate of al-
lergic in£ammation in rats resemble those of GM-
CSF, but we have no de¢nitive evidence indicating
that HPIF in the exudate is GM-CSF. In the present
study, we found that the antigen- or A23187-stimu-
lated RBL-2H3 cells also release HPIF into the me-
dium (Fig. 1). Therefore, we puri¢ed HPIF in the
conditioned medium of the A23187-stimulated
RBL-2H3 cells and concluded that the puri¢ed
HPIF is GM-CSF for the following four reasons:
(1) the amino acid sequence of the digested peptide
of HPIF was identical to rat GM-CSF (50^63) [19],
(2) there is no discrepancy in biochemical features,
molecular weight and pI value between HPIF and
human GM-CSF [3,5] (biochemical features of rat
GM-CSF have not yet been reported), (3) the levels
of GM-CSF mRNA were increased by A23187 stim-
ulation (Fig. 5), and (4) recombinant rat GM-CSF
showed histamine-production-increasing activity
(Fig. 6). Although IL-1K, TNF-K and G-CSF have
little e¡ect on HDC activity in vitro [18], injection of
these cytokines to mouse increased HDC activity in
bone marrow cells, lung, spleen and liver [20]. In
addition, IL-1 and TNF-K enhance GM-CSF-in-
duced histamine production by bone marrow cells
in vitro [21]. Thus several cytokines might collabo-
rate in histamine production in allergic in£ammatory
sites in vivo.
Mast cells trigger the anaphylactic response by re-
leasing chemical mediators, such as histamine, pros-
taglandins and leukotrienes. Mast cells might also
participate in the late phase reaction by releasing
various types of cytokine including GM-CSF. GM-
CSF enhances various functions of mature in£amma-
tory cells, such as degranulation, arachidonic acid
release and cytokine secretion from neutrophils,
superoxide anion release from macrophages, survival
of eosinophils and so on [22,23]. Since the histamine
producing cells that respond to GM-CSF are consid-
ered to be immature [17,18], the role of histamine has
been examined in relation to proliferation and di¡er-
entiation of hematopoietic progenitor cells. For ex-
ample, H2 receptor antagonists block the histamine-
induced proliferation and di¡erentiation of hemato-
poietic progenitor cells [24]. As we reported previ-
ously [1,3], histamine is produced at the late phase
following IgE-induced degranulation of mast cells,
indicating that mast cell-derived GM-CSF also in-
duces histamine production at the in£ammatory site
and exerts activity to modulate the function of ma-
ture in£ammatory cells.
In conclusion, the present study demonstrated that
when RBL-2H3 cells are stimulated with A23187 or
the antigen, they produce GM-CSF that enhances
histamine production by bone marrow cells. There-
fore, it was suggested that one candidate for HPIF in
the allergic in£ammatory site at the late phase is
GM-CSF. Further investigation is necessary to iden-
tify histamine producing cells at the in£ammatory
site that respond to GM-CSF.
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